ICAM1 and autoimmune polyendocrinopathy: The protective role of fluvastatin in APS models was later confirmed by two separate studies conducted by Ferrara et al. In the first study, using CD-1 mice exposed to IgG aPL from patients with APS, fluvastatin administration was associated with smaller thrombi, a reduced number of adherent leukocytes, and decreased levels of ICAM-1 compared with animals treated with a placebo [124].